Ozagrel

• UNSPSC Description:

  Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM[1].

• Target Antigen:

  Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Ozagrel.html

• Purity:

  99.74

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(O)/C=C/C1=CC=C(CN2C=CN=C2)C=C1

• Molecular Weight:

  228.25

• References & Citations:

  [1]Max Seidy Saito, et al. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem. 2016 Dec;31(6):1591-601.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  82571-53-7